Kodama M et al., 2017-08: In vivo shRNA and CRISPR screens in ovarian cancer xenografts identifying KPNB1 (importin beta-1) as a druggable oncogene, with ivermectin reproducing the KPNB1-dependent antitumour effect through cell cycle arrest and apoptosis.
Interestingly, ivermectin, a Food and Drug Administration-approved antiparasitic drug, showed KPNB1-dependent antitumor effects on EOC, serving as an alternative
n/a (HTML full text)
Kodama M et al., 2017-08: In vivo shRNA and CRISPR screens in ovarian cancer xenografts identifying KPNB1 (importin beta-1) as a druggable oncogene, with ivermectin reproducing the KPNB1-dependent antitumour effect through cell cycle arrest and apoptosis. Study type: in vivo shRNA/CRISPR dropout screens in human tumour xenografts + cell-line validation. N: not stated in the abstract. Country: USA (MD Anderson Cancer Center, Houston). Dose: not stated in the abstract. Funder: US government (NCI) support per publication type. Declared COI: 'The authors declare no conflict of interest.' Comparator: KPNB1 knockdown and control shRNA. Excerpt ends mid-sentence because the abstract sentence continues; the quoted words are continuous. Study type: animal.
